

[ Tue, Apr 19th 2022
] - WOPRAI



[ Mon, Mar 01st 2021
] - WOPRAI



[ Wed, Apr 08th 2020
] - WOPRAI

[ Tue, Jan 29th 2019
] - WOPRAI

[ Wed, Apr 12th 2017
] - WOPRAI


Kevin DeGeeter Initiated (ANTX) at Buy and Held Target at $22 on, Apr 19th, 2022
Kevin DeGeeter of Oppenheimer, Initiated "AN2 Therapeutics, Inc." (ANTX) at Buy and Held Target at $22 on, Apr 19th, 2022.
Kevin, nor any peers, have made any analyst calls on ANTX in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources